Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Short Interest Down 86.1% in June

Basilea Pharmaceutica AG (OTCMKTS:BPMUF) was the recipient of a significant decrease in short interest in June. As of June 30th, there was short interest totaling 228 shares, a decrease of 86.1% from the June 15th total of 1,642 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is presently ∞ days. Approximately 0.0% of the company’s stock are short sold.

Basilea Pharmaceutica Stock Performance

Shares of Basilea Pharmaceutica stock remained flat at $60.27 during midday trading on Friday. The business has a 50 day moving average price of $63.66 and a 200 day moving average price of $67.62. The company has a debt-to-equity ratio of 0.59, a current ratio of 5.11 and a quick ratio of 4.68. Basilea Pharmaceutica has a 12 month low of $59.29 and a 12 month high of $74.00.

Basilea Pharmaceutica Company Profile

Basilea Pharmaceutica AG is a Swiss biopharmaceutical company headquartered in Basel, specializing in the development and commercialization of innovative treatments for hospital‐treated diseases. The company’s research is focused primarily on anti‐infectives and oncology, with a portfolio that spans both marketed products and early‐ to late‐stage pipeline candidates. Basilea leverages medicinal chemistry expertise to address critical medical needs in fungal infections, bacterial infections and cancer.

Among its lead products is isavuconazole, a broad‐spectrum antifungal agent marketed under the trade name Cresemba.